{
  "emaEpar": [
    {
      "activeSubstance": "Pirfenidone",
      "conditionIndication": "Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis.",
      "inn": "pirfenidone",
      "marketingAuthorisationDate": "2011-02-27 01:00:00",
      "marketingAuthorisationHolder": "Roche Registration GmbH",
      "medicineName": "Esbriet",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/esbriet"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "ESBRIET",
      "indication": "1 INDICATIONS AND USAGE ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF). ( 1 )",
      "manufacturer": "Genentech, Inc.",
      "splSetId": "2e8c3537-36d7-4de5-9b5c-7a624b9a9e6e"
    }
  ],
  "id": "Pirfenidone",
  "nciThesaurus": {
    "casRegistry": "53179-13-8",
    "chebiId": "",
    "chemicalFormula": "C12H11NO",
    "definition": "An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis.",
    "fdaUniiCode": "D7NLD2JX7U",
    "identifier": "C2635",
    "preferredName": "Pirfenidone",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C257",
      "C797"
    ],
    "synonyms": [
      "PIRFENIDONE",
      "Pirfenidone",
      "pirfenidone"
    ]
  }
}